Gut Microbiome, Holobionts, Interorgan Communication and Metabolic Disorders
Holobionts and metaorganisms, gut microbiome functions, germ-free animals, gut-brain axis, dysbiosis, organ crosstalk, energy homeostasis, diabetes and obesity.
- 24 min
On this page · 16 sections
Prerequisites
- Digestion, Energy Balance, BMR, Thermoregulation and Stress — gut hormones, leptin, the arcuate nucleus and the HPA axis.
- Endocrinology, Reproduction and Neuroendocrine Regulation — insulin secretion and signalling, glucagon, incretins.
- Bioenergetics and Metabolism — glycolysis, gluconeogenesis, β-oxidation and ketogenesis, the pathways that organs exchange.
The Hook: Mice Without Microbes
How CSIR NET asks it. This is new in the revised syllabus, so expect concept questions in Part B (functions of SCFAs, germ-free phenotypes, routes of the gut–brain axis, organokine sources, diabetes types) and experiment-based questions in Part C (germ-free colonisation, faecal transfer, antibiotic or vagotomy controls, knockout mice, glucose and insulin data, diversity indices).
Metaorganisms and Holobionts
| Term | Meaning |
|---|---|
| Microbiota | The microorganisms (bacteria, archaea, fungi, protists, viruses) living in a defined habitat such as the gut |
| Microbiome | The microbiota together with their genes and functions (often used for the genes alone) |
| Holobiont | A host plus all its associated microbes, treated as a biological unit; the term was popularised by Lynn Margulis |
| Hologenome | The host genome plus all microbial genomes of the holobiont; the “hologenome concept” treats it as a possible unit of selection (debated) |
| Metaorganism | Near-synonym for holobiont, emphasising the host–microbe system as a functional whole |
| Gnotobiotic | An animal whose entire microbial content is known: germ-free, or colonised with defined species |
| Symbiosis | Living together; spans mutualism (both benefit), commensalism (one benefits, other unaffected) and parasitism |
| Pathobiont | A resident microbe that is harmless normally but can cause disease when conditions change |
Classic holobiont systems
| System | Partner | What the microbe does |
|---|---|---|
| Hawaiian bobtail squid (Euprymna scolopes) | Vibrio fischeri in the light organ | Bioluminescence, controlled by quorum sensing (LuxI/LuxR, acyl-homoserine lactone), used for counter-illumination camouflage at night; the squid expels most of the bacteria each dawn and regrows them; the bacteria’s cell-wall products (peptidoglycan fragment, LPS) trigger developmental remodelling of the light organ |
| Aphids | Buchnera aphidicola in bacteriocytes | Supplies essential amino acids missing from phloem sap; maternally transmitted, with a very reduced genome |
| Many insects | Wolbachia | Reproductive manipulation: cytoplasmic incompatibility, male killing, feminisation, parthenogenesis; Wolbachia in Aedes aegypti reduces transmission of dengue virus |
| Ruminants | Rumen bacteria, protists, fungi, methanogenic archaea | Ferment cellulose to volatile fatty acids (main energy source of the host) and microbial protein; archaea produce methane |
| Termites | Hindgut protists and bacteria | Digest lignocellulose, fix nitrogen |
| Reef-building corals | Symbiodiniaceae (dinoflagellates, “zooxanthellae”) | Photosynthate to the host; bleaching when heat stress breaks the partnership |
| Legumes (plant example) | Rhizobia in root nodules | Nitrogen fixation (compare plant physiology for the energy side) |
Transmission: vertical (from parent, e.g. Buchnera, Wolbachia: genomes shrink, partner becomes obligate) or horizontal (acquired from the environment each generation, e.g. V. fischeri: requires a selective recruitment mechanism).
The Gut Microbiome
Size and composition
- The human colon holds the densest microbial community known, on the order of 10¹¹ cells per gram of content; the stomach and upper small intestine hold far fewer (acid, bile, fast transit, O₂). Most colonic bacteria are strict anaerobes.
- The total number of bacteria in the body is now estimated to be of the same order as the number of human cells (a 2016 re-estimate replaced the old “ten to one” figure). Their combined gene set is far larger than the human genome.
- Dominant phyla in adults: Bacillota (Firmicutes) and Bacteroidota (Bacteroidetes), then Actinomycetota (Bifidobacterium), Pseudomonadota (Proteobacteria, including Escherichia) and Verrucomicrobiota (Akkermansia muciniphila, a mucin degrader). Archaea (Methanobrevibacter smithii), fungi and a large phage population are also present.
- Methods: 16S rRNA gene sequencing (who is there), shotgun metagenomics (what genes are there), metatranscriptomics, metabolomics, and gnotobiotic transfer experiments (what microbes cause).
Assembly through life
graph LR
B["Birth: vaginal delivery seeds
maternal vaginal and gut taxa;
Caesarean: more skin-associated taxa"] --> M["Milk: human milk oligosaccharides
feed Bifidobacterium"]
M --> W["Weaning: solid food,
diversity rises sharply"]
W --> A["By about 2-3 years: adult-like,
relatively stable community"]
A --> O["Old age, antibiotics, diet,
illness: diversity can fall"]Human milk oligosaccharides are indigestible by the infant; they act as prebiotics that select for bifidobacteria able to use them.
What the microbiota does
| Function | Mechanism | Host consequence |
|---|---|---|
| Fibre fermentation | Polysaccharides the host cannot digest → short-chain fatty acids (SCFAs): acetate, propionate, butyrate (acetate the most abundant) | Butyrate is the preferred fuel of colonocytes; propionate is a substrate for hepatic and intestinal gluconeogenesis; acetate reaches peripheral tissues; SCFAs supply a meaningful fraction of energy, especially on high-fibre diets |
| SCFA signalling | GPCRs FFAR2 (GPR43) and FFAR3 (GPR41); butyrate also inhibits histone deacetylases | GLP-1 and PYY release from L cells; expansion of colonic regulatory T cells; maintenance of the epithelial barrier |
| Bile-acid metabolism | Bile salt hydrolases deconjugate; 7α-dehydroxylation makes secondary bile acids (deoxycholic, lithocholic) | Alters signalling through FXR (nuclear receptor) and TGR5 (GPCR); affects lipid and glucose metabolism; some bile acids inhibit Clostridioides difficile germination |
| Vitamin synthesis | Vitamin K₂ (menaquinones), several B vitamins (biotin, folate) | Contributes to host supply (B₁₂ made in the colon is largely beyond the ileal absorption site) |
| Tryptophan metabolism | Indoles and other derivatives → aryl hydrocarbon receptor (AhR); microbes also promote serotonin synthesis by enterochromaffin cells | Barrier function, immune regulation; most body serotonin is made in the gut |
| Colonisation resistance | Competition for nutrients and niches, bacteriocins, secondary bile acids, pH | Protection from pathogens (C. difficile, Salmonella); lost after broad-spectrum antibiotics |
| Immune education | Segmented filamentous bacteria induce Th17 cells in mice; Bacteroides fragilis polysaccharide A and certain Clostridia induce Treg cells; microbes drive secretory IgA | Balanced mucosal immunity; development of gut-associated lymphoid tissue |
| Xenobiotic and drug metabolism | Microbial enzymes activate, inactivate or reactivate drugs (deconjugating glucuronides) | Inter-individual differences in drug response and toxicity |
| Choline and carnitine → TMA | Microbial TMA lyases; liver FMO3 oxidises TMA to TMAO | High TMAO is associated with atherosclerotic disease in human and mouse studies |
Germ-free and gnotobiotic animals
How they are made: Caesarean derivation into sterile isolators (or sterile hatching for chicks, fish, flies), sterilised food, water and bedding, with regular checks (culture, PCR) for contamination. Colonisation with one species (mono-association), a defined consortium, or a whole donor community (faecal microbiota transfer) then tests what microbes do.
| System | Germ-free phenotype (mice unless stated) |
|---|---|
| Gut anatomy | Greatly enlarged caecum; slower epithelial turnover; altered motility |
| Gut immunity | Small Peyer’s patches and mesenteric nodes, fewer IgA plasma cells and intestinal T cells (Th17, Treg); thinner mucus layer |
| Metabolism | Less body fat than conventional mice despite higher food intake; resistant to diet-induced obesity; conventionalisation rapidly increases fat stores |
| Energy harvest | More undigested polysaccharide lost in faeces (no SCFA production) |
| Stress axis | Exaggerated HPA response (ACTH, corticosterone) to restraint stress, normalised by early-life colonisation but much less by colonisation later |
| Brain | Altered anxiety-like and social behaviours, changes in blood–brain barrier permeability and immature microglia have been reported |
| Drug and bile-acid profiles | Only conjugated primary bile acids; no secondary bile acids |
The fat-harvest experiments (associated with Jeffrey Gordon’s laboratory):
- Conventionalising germ-free mice increases body fat within about two weeks without increased food intake. Proposed mechanisms: more SCFA and monosaccharide absorption, increased hepatic lipogenesis, and microbial suppression of the intestinal LPL inhibitor ANGPTL4 (also called Fiaf), which increases fat storage in adipose tissue.
- Microbiota from obese (ob/ob) mice transferred into germ-free recipients causes more fat gain than microbiota from lean littermates: the obese community harvests more energy from the same diet.
- Microbiota from human twins discordant for obesity, transferred into germ-free mice, transmits the difference in adiposity; co-housing lets “lean” microbes invade and prevent the extra gain (mice eat each other’s faeces), but only on a healthy, high-fibre diet.
Early studies linked obesity to a higher Firmicutes-to-Bacteroidetes ratio; this ratio has not proved a consistent marker in later human studies, so treat it as a historical observation, not a rule.
The Gut–Brain Axis
The gut–brain axis is the bidirectional communication between the gut (with its microbiota) and the central nervous system.
graph TD
MIC["Gut microbiota"] --> MET["Metabolites: SCFAs, tryptophan
derivatives, secondary bile acids,
neurotransmitter-like molecules (GABA)"]
MIC --> IMM["Immune signals:
cytokines, trained immune cells"]
MET --> EEC["Enteroendocrine cells:
serotonin, GLP-1, PYY, CCK"]
EEC --> VAG["Vagal afferents to
nucleus tractus solitarius"]
MET --> BLOOD["Systemic circulation,
blood-brain barrier, microglia"]
IMM --> BLOOD
VAG --> BRAIN["Brain: appetite, mood,
stress responses, behaviour"]
BLOOD --> BRAIN
BRAIN -- "HPA axis (cortisol),
autonomic outflow" --> GUT["Gut: motility, secretion,
permeability, mucus"]
GUT --> MICRoutes, gut to brain:
- Vagus nerve. Vagal afferents sense gut hormones, stretch and metabolites. Some enteroendocrine cells make synapse-like contacts with vagal fibres, allowing fast signalling. In a widely cited mouse study a Lactobacillus strain reduced anxiety-like behaviour and changed brain GABA-receptor expression, and these effects were absent in vagotomised mice, the standard control for a vagal route.
- Endocrine. Gut hormones (GLP-1, PYY, CCK, ghrelin) reach the hypothalamus and brainstem; microbial effects on serotonin production by enterochromaffin cells act mainly in the gut and on vagal afferents (serotonin itself does not cross the blood–brain barrier).
- Immune. Microbial products (e.g. LPS) and cytokines signal to the brain; microbes shape microglial maturation.
- Metabolic. SCFAs, tryptophan metabolites (kynurenine pathway, indoles) and secondary bile acids act on distant receptors.
Routes, brain to gut: stress via the HPA axis and sympathetic outflow alters motility, secretion, mucus, blood flow and permeability, which change the niche and therefore the microbiota.
Clinical associations: irritable bowel syndrome (a classic disorder of gut–brain interaction), mood disorders, autism spectrum conditions and Parkinson’s disease (some evidence that α-synuclein pathology may begin in the gut) have all been associated with microbiome differences. In humans, most of these are correlations; causality is established mainly in animal models. Probiotics proposed to act on mood are sometimes called psychobiotics.
Dysbiosis
Dysbiosis is a change in microbiota composition or function associated with disease. Common features:
- Loss of diversity (fewer taxa, less even distribution).
- Loss of beneficial taxa, e.g. butyrate producers such as Faecalibacterium prausnitzii (reduced in Crohn’s disease).
- Bloom of pathobionts, e.g. Enterobacteriaceae (Proteobacteria) in inflamed guts, where host-derived nitrate and oxygen favour facultative anaerobes.
- Barrier failure and metabolic endotoxaemia: increased gut permeability lets LPS enter blood → TLR4 activation → low-grade inflammation that impairs insulin signalling (a proposed link between high-fat diets and insulin resistance in mice).
| Cause of dysbiosis | Example |
|---|---|
| Antibiotics | Broad-spectrum courses → loss of colonisation resistance → C. difficile infection |
| Diet | Low-fibre, high-fat diets reduce SCFA producers; microbes then degrade the mucus layer for food |
| Birth mode and early life | Caesarean delivery, formula feeding, early antibiotics alter early colonisation |
| Inflammation, infection, drugs | IBD, enteric infection, proton-pump inhibitors, metformin (which itself changes the microbiota) |
| Disease | Microbiome association |
|---|---|
| Recurrent C. difficile infection | Strongest causal evidence; faecal microbiota transplantation cures most recurrent cases |
| Inflammatory bowel disease | Reduced diversity, fewer butyrate producers, more Proteobacteria |
| Colorectal cancer | Fusobacterium nucleatum enrichment; colibactin-producing (pks⁺) E. coli cause DNA damage |
| Obesity, type 2 diabetes | Reduced diversity and SCFA producers in many studies; functional changes more consistent than taxonomic ones |
| Atherosclerosis | TMAO pathway (association) |
Interventions: probiotics (live beneficial microbes), prebiotics (substrates that selectively feed beneficial microbes: inulin, fructo- and galacto-oligosaccharides, milk oligosaccharides), synbiotics (both), postbiotics (inactivated microbes or their products), dietary fibre, and FMT.
Measuring diversity. The Shannon index H′ = −Σ pᵢ ln pᵢ rises with both the number of taxa (richness) and how evenly they are represented; its maximum for S taxa is ln S, and evenness = H′/ln S.
Interorgan Communication
Organs coordinate through hormones (classic endocrine glands plus “organokines” from tissues not usually seen as glands), nerves (autonomic and vagal sensory), metabolites and extracellular vesicles carrying proteins and microRNAs.
| Organ (organokine class) | Signal | Main actions |
|---|---|---|
| Adipose tissue (adipokines) | Leptin | Signals fat stores to hypothalamus; ↓ appetite, permits reproduction |
| Adiponectin | Insulin-sensitising (AMPK activation in liver and muscle), anti-inflammatory; lower in obesity | |
| TNF-α, IL-6, resistin (rodents) | Inflammatory; impair insulin signalling | |
| Skeletal muscle (myokines) | IL-6 from contracting muscle | Increases hepatic glucose output and lipolysis during exercise |
| Myostatin (GDF-8) | Negative regulator of muscle mass; loss-of-function mutations cause double muscling (Belgian Blue cattle, myostatin-knockout mice) | |
| Irisin (from FNDC5) | Proposed to promote browning of white fat; its physiological role in humans is debated | |
| Liver (hepatokines) | IGF-1 | Mediates GH growth effects |
| FGF21 | Released in fasting and on ketogenic or protein-poor diets; acts with the co-receptor β-Klotho; promotes fat oxidation and ketogenesis; improves insulin sensitivity in rodents | |
| Fetuin-A, angiotensinogen, hepcidin | Insulin resistance (fetuin-A); blood pressure; iron | |
| Gut | GLP-1, GIP, PYY, ghrelin, CCK; FGF19 (FGF15 in mice) from ileum | Incretins, appetite; FGF19 tells the liver to stop making bile acids (represses CYP7A1) after FXR activation by returning bile acids |
| Bone | FGF23; osteocalcin | Phosphate and vitamin D control (FGF23); osteocalcin affects glucose metabolism in mouse studies |
| Heart | ANP, BNP | Natriuresis; ANP also stimulates lipolysis |
| Kidney | EPO, renin, calcitriol | Red-cell mass, blood pressure, calcium |
| Brown fat (batokines) | FGF21, others | Thermogenesis, systemic metabolism |
Classic metabolic loops between organs
| Loop | Route | Purpose |
|---|---|---|
| Cori cycle | Muscle and red-cell lactate → liver gluconeogenesis → glucose → muscle | Recycles carbon; shifts the energy cost of gluconeogenesis to the liver |
| Glucose–alanine cycle | Muscle alanine (carrying amino nitrogen) → liver → urea + glucose | Carries nitrogen safely to the liver during fasting and exercise |
| Glucose–fatty acid (Randle) cycle | High fatty-acid oxidation in muscle → acetyl-CoA, NADH and citrate inhibit PDH and PFK-1 | Fuel competition: fat use spares glucose (a contributor to insulin resistance when chronic) |
| Ketone bodies | Liver makes acetoacetate and β-hydroxybutyrate (it cannot use them) → brain, heart, muscle | Spares glucose and muscle protein in prolonged fasting |
| Enterohepatic circulation | Bile acids: liver → gut → ileum → liver | Recycles bile acids; FXR–FGF19 feedback |
| Adipose–liver axis | Lipolysis releases glycerol (→ gluconeogenesis) and fatty acids (→ ketogenesis, VLDL) | Fasting fuel supply |
Energy Homeostasis
The fed–fasting cycle
| State | Hormones | Liver | Muscle | Adipose | Brain fuel |
|---|---|---|---|---|---|
| Fed (absorptive) | Insulin ↑, glucagon ↓ | Glycogen synthesis, glycolysis, lipogenesis, VLDL export | Glucose uptake (GLUT4), glycogen and protein synthesis | Glucose uptake, TAG storage (LPL active) | Glucose |
| Post-absorptive / early fast | Insulin ↓, glucagon ↑ | Glycogenolysis first, then gluconeogenesis | Uses fatty acids; releases alanine, lactate | Lipolysis (HSL, ATGL) | Glucose |
| Prolonged fasting | Insulin very low, glucagon, cortisol | Gluconeogenesis (lactate, glycerol, alanine), ketogenesis | Protein breakdown slows as ketones rise | Lipolysis | Ketone bodies supply a large share; glucose need falls |
- The brain normally depends on glucose; red cells always do (no mitochondria). Liver glycogen lasts roughly a day of fasting; after that, glucose comes from gluconeogenesis.
- Fasting blood glucose is normally about 70–100 mg/dL (about 3.9–5.6 mM).
- The insulin-to-glucagon ratio, not either hormone alone, sets the liver’s direction (storage vs release).
Cellular and central energy sensors
| Sensor | Senses | When active | Main effects |
|---|---|---|---|
| AMPK | Rising AMP/ATP (and ADP/ATP) ratio | Exercise, fasting, hypoxia; activated by adiponectin and indirectly by metformin | Switches on catabolism (fatty-acid oxidation, glucose uptake, autophagy); switches off anabolism (inhibits ACC, so malonyl-CoA falls; inhibits mTORC1) |
| mTORC1 | Amino acids, insulin/growth factors, energy | Fed state | Protein synthesis, lipogenesis, growth; inhibits autophagy |
| Sirtuins (SIRT1) | NAD⁺ levels | Fasting, calorie restriction | Deacetylation of metabolic regulators (e.g. PGC-1α) |
| Hypothalamus (arcuate nucleus) | Leptin, insulin, ghrelin, nutrients | Continuous | Appetite and sympathetic outflow (previous page) |
| β cell glucokinase | Blood glucose | Continuous | Insulin release |
Metabolic Disorders
Diabetes mellitus
| Feature | Type 1 | Type 2 |
|---|---|---|
| Cause | Autoimmune destruction of β cells (T cells; autoantibodies to insulin, GAD65, IA-2, ZnT8) | Insulin resistance plus progressive β-cell failure |
| Onset | Often in childhood or youth, but any age | Usually adults; increasingly in young people with obesity |
| Insulin / C-peptide | Very low | Normal or high early; falls later |
| Body build | Often lean | Usually overweight, central obesity |
| Ketoacidosis | Common presenting emergency | Uncommon |
| Genetics | HLA-linked (DR3, DR4); lower concordance in twins | Strong polygenic heritability; higher twin concordance |
| Treatment | Insulin essential | Lifestyle, metformin, incretin drugs, SGLT2 inhibitors, later insulin |
Diagnostic thresholds (as widely used, e.g. by the American Diabetes Association): fasting plasma glucose ≥ 126 mg/dL (7.0 mM); 2-hour value in a 75 g oral glucose tolerance test ≥ 200 mg/dL (11.1 mM); HbA1c ≥ 6.5%; or random glucose ≥ 200 mg/dL with symptoms.
Diabetic ketoacidosis: absolute insulin lack with high glucagon → unrestrained lipolysis → hepatic ketogenesis (acetoacetate, β-hydroxybutyrate) → high anion-gap metabolic acidosis, Kussmaul breathing; hyperglycaemia → osmotic diuresis → dehydration and K⁺ loss (plasma K⁺ may look normal or high because acidosis and insulin lack shift K⁺ out of cells). See acid–base.
Mechanisms of insulin resistance (type 2):
- Ectopic lipid in liver and muscle → diacylglycerol activates novel PKC isoforms (PKCε in liver, PKCθ in muscle) → serine phosphorylation of IRS proteins → weaker PI3K–Akt signalling; ceramides also implicated.
- Inflammation: macrophages accumulate in expanding adipose tissue (“crown-like structures”) and secrete TNF-α and IL-6; JNK and IKKβ phosphorylate IRS-1 on serine.
- Adipose failure: when subcutaneous fat cannot expand, lipid spills into viscera, liver and muscle; adiponectin falls.
- β-cell exhaustion from glucotoxicity and lipotoxicity converts compensated insulin resistance into diabetes.
Monogenic forms: MODY (maturity-onset diabetes of the young; autosomal dominant), e.g. glucokinase mutations (raised glucose set point, mild) and HNF1A mutations; neonatal diabetes from activating K_ATP mutations (treatable with sulfonylureas).
| Drug | Organ / target | Effect |
|---|---|---|
| Metformin | Mainly liver | Lowers hepatic glucose output (mitochondrial effects; activates AMPK) |
| GLP-1 receptor agonists | β cells, brain, stomach | Glucose-dependent insulin secretion, ↓ glucagon, slower gastric emptying, weight loss via satiety |
| DPP-4 inhibitors (gliptins) | Plasma enzyme | Prolong endogenous GLP-1 and GIP |
| SGLT2 inhibitors | Kidney proximal tubule | Glycosuria, lower glucose; cardiovascular and renal benefits |
| Thiazolidinediones | PPARγ (adipose) | Adipocyte differentiation, ↑ adiponectin, insulin sensitisation |
| Sulfonylureas | β-cell K_ATP | Insulin release regardless of glucose (hypoglycaemia risk) |
Bariatric surgery (e.g. gastric bypass) often improves type 2 diabetes within days, before much weight is lost, partly through raised post-meal GLP-1 and PYY and changes in bile acids and microbiota: interorgan communication made visible.
Obesity and the metabolic syndrome
- Body mass index = weight (kg) / height² (m²). WHO adult categories: 18.5–24.9 normal, 25–29.9 overweight, ≥ 30 obese; lower cut-offs are used for Asian populations because metabolic risk rises at lower BMI.
- Monogenic obesity (rare): leptin, leptin receptor, POMC, MC4R (the commonest). Most obesity is polygenic and environmental.
- Metabolic syndrome: a cluster of central obesity, high triglycerides, low HDL cholesterol, raised blood pressure and raised fasting glucose; definitions (NCEP ATP III, IDF) require any three (ATP III) or central obesity plus two (IDF). It predicts type 2 diabetes and cardiovascular disease.
- Fatty liver disease linked to metabolic dysfunction (formerly NAFLD, now termed MASLD) is the hepatic face of the syndrome; it can progress to steatohepatitis, fibrosis and cirrhosis.
Insulin resistance index (HOMA-IR):
$$\text{HOMA-IR} = \frac{\text{fasting insulin }(\mu\text{U/mL}) \times \text{fasting glucose (mM)}}{22.5}$$A value of 1 corresponds to the reference population of the original model; higher values indicate greater insulin resistance.
Other metabolic disorders often tested
| Disorder | Defect | Feature |
|---|---|---|
| Familial hypercholesterolaemia | LDL receptor (also ApoB, PCSK9 gain of function) | Very high LDL, early heart disease; Brown and Goldstein’s work on receptor-mediated endocytosis |
| Lipoprotein lipase deficiency | LPL | Chylomicronaemia, pancreatitis |
| Gout | Excess uric acid (overproduction or underexcretion) | Urate crystals in joints; allopurinol inhibits xanthine oxidase |
| Phenylketonuria | Phenylalanine hydroxylase | Intellectual disability if untreated; low-Phe diet |
| Glycogen storage disease type I (von Gierke) | Glucose-6-phosphatase | Fasting hypoglycaemia, lactic acidosis, enlarged liver |
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| Microbiota: the organisms | vs | Microbiome: organisms and their genes/functions |
| Germ-free: no microbes | vs | Gnotobiotic: all microbes known (includes germ-free and defined colonisation) |
| Probiotic: live microbes | vs | Prebiotic: substrate feeding beneficial microbes |
| Vertical transmission (Buchnera, Wolbachia) | vs | Horizontal acquisition (Vibrio fischeri) |
| Primary bile acids: made in liver | vs | Secondary bile acids: made by gut bacteria |
| FXR: nuclear receptor; FGF19 feedback | vs | TGR5: GPCR; GLP-1 release, energy expenditure |
| Leptin: high in obesity (resistance) | vs | Adiponectin: low in obesity |
| Cori cycle: lactate carbon | vs | Glucose–alanine cycle: carries amino nitrogen too |
| Type 1 diabetes: autoimmune, insulin absent | vs | Type 2: insulin resistance, β-cell failure |
| AMPK: low energy, catabolic | vs | mTORC1: nutrients plentiful, anabolic |
Common Mistakes
Practice
All questions below are original practice questions written in CSIR NET style. They are not previous-year questions.
Level 1: Foundation
- Which short-chain fatty acid is the main energy source of colonocytes?
- What does “gnotobiotic” mean?
- Which adipokine is insulin-sensitising and reduced in obesity?
Answers
- Butyrate.
- An animal whose complete microbial content is known: germ-free or colonised with defined microbes.
- Adiponectin.
Level 2: Part B Style
Q1 (practice). Which phenotype is characteristic of germ-free mice compared with conventionally raised mice?
- (a) Smaller caecum and more body fat
- (b) Enlarged caecum and resistance to diet-induced obesity
- (c) More IgA plasma cells in the gut
- (d) Higher levels of secondary bile acids
Answer and explanation
(b). Germ-free mice have a greatly enlarged caecum, less fat and resistance to diet-induced obesity. They have fewer IgA plasma cells and no secondary bile acids (those require bacterial 7α-dehydroxylation).
Q2 (practice). Bile acids returning to the ileum activate FXR in enterocytes. The resulting signal to the liver and its effect are:
- (a) GLP-1; increased bile-acid synthesis
- (b) FGF19; repression of CYP7A1 and reduced bile-acid synthesis
- (c) Secretin; increased bile flow
- (d) FGF23; reduced phosphate reabsorption
Answer and explanation
(b). Ileal FXR induces FGF19 (FGF15 in mice), which travels in portal blood to hepatocytes and represses CYP7A1, the rate-limiting enzyme of bile-acid synthesis: a gut–liver negative feedback loop.
Q3 (practice). A man weighs 95 kg and is 1.75 m tall. His fasting glucose is 6.3 mM and fasting insulin 15 µU/mL. His BMI and HOMA-IR are approximately:
- (a) 31.0 and 4.2
- (b) 54.3 and 4.2
- (c) 31.0 and 0.42
- (d) 27.1 and 2.1
Answer and explanation
(a). BMI = 95 / 1.75² = 95 / 3.0625 = 31.0 (obese by WHO adult cut-off). HOMA-IR = (15 × 6.3)/22.5 = 94.5/22.5 = 4.2, indicating substantial insulin resistance.
Q4 (practice). Which pairing of symbiont and its main contribution to the host is correct?
- (a) Buchnera in aphids: bioluminescence
- (b) Vibrio fischeri in the bobtail squid: essential amino acids
- (c) Wolbachia in insects: reproductive manipulation such as cytoplasmic incompatibility
- (d) Zooxanthellae in corals: nitrogen fixation in root nodules
Answer and explanation
(c). Buchnera supplies essential amino acids; V. fischeri provides light; zooxanthellae supply photosynthate (root nodules are legume–rhizobium symbioses).
Level 3: Part C Style
Q1 (practice). Germ-free mice were colonised with caecal microbiota from (i) conventionally raised lean mice or (ii) genetically obese (ob/ob) mice. All recipients ate the same chow in equal amounts. After two weeks:
| Group | Gain in body fat (%) | Faecal energy (kcal/g) | Caecal SCFAs (relative) |
|---|---|---|---|
| Germ-free (not colonised) | 2 | 3.8 | 0.1 |
| Lean donor | 25 | 3.4 | 1.0 |
| Obese donor | 45 | 3.1 | 1.6 |
Which conclusions are justified?
(A) Microbiota colonisation increases fat gain without increased food intake. (B) The obese-donor community extracts more energy from the same diet. (C) The data prove that microbiota cause obesity in humans. (D) Higher SCFA production is consistent with greater fermentation of dietary polysaccharide.
- (a) A, B and D only
- (b) A and C only
- (c) B, C and D only
- (d) A, B, C and D
Answer and worked solution
(a) A, B and D only.
- (A) Intake was equal, yet colonised mice gained more fat. Justified.
- (B) Less energy left in faeces (3.1 vs 3.4 kcal/g) and more fat gain with the obese-donor community. Justified.
- (D) More SCFA means more fermentation of polysaccharides the host cannot digest. Justified.
- (C) Not justified: this is a mouse transfer experiment showing sufficiency in mice; human causation needs other evidence.
Q2 (practice). Two faecal samples were analysed at the genus level.
| Genus | Sample P (relative abundance) | Sample Q (relative abundance) |
|---|---|---|
| 1 | 0.25 | 0.70 |
| 2 | 0.25 | 0.10 |
| 3 | 0.25 | 0.10 |
| 4 | 0.25 | 0.10 |
(i) Calculate the Shannon index (natural log) for each. (ii) Calculate evenness for each. (iii) Which sample better fits the dysbiosis seen after a course of broad-spectrum antibiotics, and why?
Answer and worked solution
- P: H′ = −4 × 0.25 ln 0.25 = ln 4 = 1.386. Q: H′ = −[0.70 ln 0.70 + 3 × 0.10 ln 0.10] = −[0.70 × (−0.357) + 0.30 × (−2.303)] = 0.250 + 0.691 = 0.940.
- Maximum for 4 genera = ln 4 = 1.386. Evenness P = 1.00; Q = 0.940/1.386 = 0.68.
- Q. Same richness, but one genus dominates (low evenness, low H′). Loss of diversity with the bloom of a few resistant taxa is typical after antibiotics. (Real antibiotic dysbiosis usually lowers richness too.)
Q3 (practice). In a mouse study, a probiotic Lactobacillus strain reduced anxiety-like behaviour and lowered stress-induced corticosterone. The effects disappeared in mice that had undergone subdiaphragmatic vagotomy. Germ-free mice showed an exaggerated corticosterone response to restraint stress that was normalised only if they were colonised in early life.
Which statements are correct?
(A) The probiotic’s behavioural effect requires an intact vagal pathway. (B) The data show that the probiotic acts by producing GABA that crosses the blood–brain barrier. (C) The germ-free data indicate a developmental window in which microbes shape the HPA axis. (D) A proper control for (A) is a sham-operated group given the probiotic.
- (a) A, C and D only
- (b) A and B only
- (c) B and C only
- (d) A, B, C and D
Answer and worked solution
(a) A, C and D only.
- (A) Loss of effect after vagotomy shows the vagus is necessary. Correct.
- (B) Not shown: the vagal requirement argues against a purely blood-borne route, and no measurement of GABA transport was made. Wrong.
- (C) Early but not late colonisation normalised the response: a sensitive period. Correct.
- (D) Sham surgery controls for the effects of the operation itself. Correct.
Quick Revision Table
| Item | Fact |
|---|---|
| Holobiont | Host + microbes as one unit (Margulis); hologenome = combined genomes |
| Gnotobiotic | All microbes known (germ-free or defined) |
| Squid–Vibrio | Light organ; quorum sensing (LuxI/LuxR); morphogenesis signal |
| Aphid–Buchnera | Essential amino acids; vertical transmission |
| Wolbachia | Cytoplasmic incompatibility; dengue control in Aedes |
| Colon density | about 10¹¹ cells per gram; mostly strict anaerobes |
| Dominant phyla | Bacillota (Firmicutes), Bacteroidota (Bacteroidetes) |
| Bacteria : human cells | Same order of magnitude (not 10:1) |
| SCFAs | Acetate (most), propionate (liver gluconeogenesis), butyrate (colonocyte fuel, HDAC inhibitor) |
| SCFA receptors | FFAR2 (GPR43), FFAR3 (GPR41) |
| Bile acids | Bacteria deconjugate and make secondary; FXR → FGF19 → ↓ CYP7A1; TGR5 → GLP-1 |
| TMAO | Choline/carnitine → TMA (microbes) → TMAO (liver FMO3) |
| Germ-free mice | Big caecum, weak gut immunity, lean, obesity-resistant, exaggerated HPA response |
| Gut–brain routes | Vagus, endocrine, immune, metabolites (VEIN); brain → gut via HPA, autonomic |
| Dysbiosis | ↓ Diversity, ↓ butyrate producers, ↑ Proteobacteria, LPS endotoxaemia |
| FMT | Most effective for recurrent C. difficile |
| Shannon index | H′ = −Σ p ln p; evenness = H′/ln S |
| Adipokines | Leptin ↑, adiponectin ↓ in obesity |
| Myostatin | GDF-8; loss → double muscling |
| FGF21 | Fasting hepatokine; β-Klotho |
| Loops | Cori (lactate), glucose–alanine, Randle, ketone bodies, enterohepatic |
| AMPK / mTORC1 | Low energy catabolic / fed anabolic |
| Diabetes criteria | FPG ≥ 126 mg/dL; 2-h OGTT ≥ 200; HbA1c ≥ 6.5% |
| T1 vs T2 | Autoimmune, no insulin, DKA vs resistance + β-cell failure |
| HOMA-IR | Insulin (µU/mL) × glucose (mM) / 22.5 |
| BMI | kg/m²; ≥ 25 overweight, ≥ 30 obese (WHO) |
| Monogenic obesity | MC4R most common; leptin, LEPR, POMC |
Key Takeaways
What’s Next
- Quick Revision — the whole unit on one page.
- Digestion, Energy Balance, BMR, Thermoregulation and Stress — revisit appetite control and the stress axis.
- Endocrinology, Reproduction and Neuroendocrine Regulation — insulin secretion and signalling in detail.
- Translation, Protein Processing and Degradation — mTORC1 and protein synthesis control at the molecular level.